Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.38 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24527009 | 0.82 | KCNH2 (0.40) | PARP1 | |
| SCHEMBL15039527 | 0.81 | CHRNB2 (0.46) | PARP1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL21723224 | 0.81 | CHRNB2 (0.46) | PARP1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL18704814 | 0.81 | CHRNB2 (0.46) | PARP1CHRNB2CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL15017116 | 0.79 | CHRNB2 (0.44) | PARP1CHRNB2CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL15017117 | 0.79 | CHRNB2 (0.44) | PARP1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL9947719 | 0.76 | PARP1 (0.42) | PARP1PARP2 | |
| SCHEMBL22089706 | 0.76 | CHRNB2 (0.40) | PARP1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3333833 | 0.76 | PARP1 (0.50) | PARP1PARP2PARP3CHRNB2CHRNA7 | |
| SCHEMBL3244198 | 0.76 | PARP1 (0.44) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION | 2021-06-29 | — | — | US | disclosed |
| US-10370379-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2019-06-06 | — | — | US | disclosed |
| US-20170145018-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | BLUEPRINT MEDICINES CORPORATION | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046697-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | PARP1 3401/4885PARP2 2870/4885MAP4K4 1149/4885 |
| US-10370379-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK3, NTRK2, NTRK1 | PARP1 3199/4885PARP2 2761/4885MAP4K4 1236/4885 |
| US-20190169194-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK3, NTRK2, NTRK1 | PARP1 3401/4885PARP2 2870/4885MAP4K4 1149/4885 |
| US-20170145018-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK | NTRK2, NTRK3, NTRK1 | PARP1 3183/4885PARP2 2899/4885MAP4K4 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.